Latent vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 41)
Latent logo

Latent

EmergingHealthcare

General

Healthcare AI automating prior authorization documentation by reviewing patient records; $13.1M from General Catalyst and YC achieving $2.4M revenue competing with Cohere Health for pharmacy workflow automation.

AI VisibilityBeta
Overall Score
C41
Category Rank
#339 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
36
Gemini
43

About

Latent is a San Francisco-based healthcare AI company automating clinical operations for pharmacy and medication access workflows — using AI to review patient medical records, generate evidence-based prior authorization documentation, and streamline the clinical justification process that currently requires pharmacists and clinical staff to spend significant time on administrative documentation that delays patients' access to medications. Founded in 2022 and a Y Combinator W23 graduate, Latent raised $13.1 million from General Catalyst and Y Combinator, achieving $2.4 million in revenue in 2024.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

41
Overall Score
93
#339
Category Rank
#1
82
AI Consensus
80
stable
Trend
stable
39
ChatGPT
94
36
Perplexity
89
43
Gemini
94
43
Claude
92
40
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.